Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 28 May 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan record..
- 15 Jan 2014 Status changed from not yet recruiting to recruiting as reported by the University Hospital Medical Information Network - Japan record.
- 03 Dec 2013 New trial record